Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cavia porcellus skin extract is a non-standardized allergenic extract derived from the skin, hair, and dander of guinea pigs (Cavia porcellus). [1, 3, 4] It is used as a diagnostic agent to identify individuals with IgE-mediated allergies to guinea pigs. [2, 8] The extract is administered via skin testing (percutaneous or intradermal) and provokes a localized allergic reaction in sensitized individuals, which helps confirm allergy to guinea pig allergens. [1, 8] This product is often used for people who have exposure to guinea pigs as pets or in laboratory settings and present with symptoms like allergic rhinitis or asthma. [8, 10] It is distributed by companies specializing in allergy diagnostics and immunotherapy, such as ALK-Abelló, Inc. and Nelco Laboratories, Inc. [7, 9, 11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cavia porcellus skin extract.